AstraZeneca (NASDAQ:AZN) Releases Earnings Results, Misses Estimates By $0.05 EPS

AstraZeneca (NASDAQ:AZN) released its quarterly earnings results on Thursday. The company reported $1.05 earnings per share for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.05), Zacks reports. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%.

AstraZeneca Stock Up 3.6 %

Shares of NASDAQ AZN traded up $2.55 during midday trading on Thursday, reaching $73.49. 4,250,015 shares of the company’s stock were exchanged, compared to its average volume of 4,930,018. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. AstraZeneca has a 52-week low of $60.47 and a 52-week high of $87.68. The business’s fifty day moving average price is $67.27 and its two-hundred day moving average price is $73.70. The stock has a market capitalization of $227.90 billion, a PE ratio of 35.17, a price-to-earnings-growth ratio of 1.18 and a beta of 0.46.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.